Susanne Petri, Torsten Grehl, Julian Grosskreutz, Martin Hecht, Andreas Hermann, Sarah Jesse, Paul Lingor, Wolfgang Löscher, André Maier, Benedikt Schoser, Marcus Weber, Albert C Ludolph
{"title":"德国神经病学学会(Deutsche Gesellschaft fr Neurologie)指南“运动神经元疾病”。","authors":"Susanne Petri, Torsten Grehl, Julian Grosskreutz, Martin Hecht, Andreas Hermann, Sarah Jesse, Paul Lingor, Wolfgang Löscher, André Maier, Benedikt Schoser, Marcus Weber, Albert C Ludolph","doi":"10.1186/s42466-023-00251-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In 2021, the Deutsche Gesellschaft für Neurology published a new guideline on diagnosis and therapy of motor neuron disorders. Motor neuron disorders affect upper motor neurons in the primary motor cortex and/or lower motor neurons in the brain stem and spinal cord. The most frequent motor neuron disease amyotrophic lateral sclerosis (ALS) is a rapidly progressive disease with an average life expectancy of 2-4 years with a yearly incidence of 3.1/100,000 in Central Europe (Rosenbohm et al. in J Neurol 264(4):749-757, 2017. https://doi.org/10.1007/s00415-017-8413-3 ). It is considered a rare disease mainly due to its low prevalence as a consequence of short disease duration.</p><p><strong>Recommendations: </strong>These guidelines comprise recommendations regarding differential diagnosis, neuroprotective therapies and multidisciplinary palliative care including management of respiration and nutrition as well as provision of assistive devices and end-of-life situations.</p><p><strong>Conclusion: </strong>Diagnostic and therapeutic guidelines are necessary due the comparatively high number of cases and the aggressive disease course. Given the low prevalence and the severe impairment of patients, it is often impossible to generate evidence-based data so that ALS guidelines are partially dependent on expert opinion.</p>","PeriodicalId":19169,"journal":{"name":"Neurological Research and Practice","volume":"5 1","pages":"25"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10268388/pdf/","citationCount":"1","resultStr":"{\"title\":\"Guideline \\\"Motor neuron diseases\\\" of the German Society of Neurology (Deutsche Gesellschaft für Neurologie).\",\"authors\":\"Susanne Petri, Torsten Grehl, Julian Grosskreutz, Martin Hecht, Andreas Hermann, Sarah Jesse, Paul Lingor, Wolfgang Löscher, André Maier, Benedikt Schoser, Marcus Weber, Albert C Ludolph\",\"doi\":\"10.1186/s42466-023-00251-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>In 2021, the Deutsche Gesellschaft für Neurology published a new guideline on diagnosis and therapy of motor neuron disorders. Motor neuron disorders affect upper motor neurons in the primary motor cortex and/or lower motor neurons in the brain stem and spinal cord. The most frequent motor neuron disease amyotrophic lateral sclerosis (ALS) is a rapidly progressive disease with an average life expectancy of 2-4 years with a yearly incidence of 3.1/100,000 in Central Europe (Rosenbohm et al. in J Neurol 264(4):749-757, 2017. https://doi.org/10.1007/s00415-017-8413-3 ). It is considered a rare disease mainly due to its low prevalence as a consequence of short disease duration.</p><p><strong>Recommendations: </strong>These guidelines comprise recommendations regarding differential diagnosis, neuroprotective therapies and multidisciplinary palliative care including management of respiration and nutrition as well as provision of assistive devices and end-of-life situations.</p><p><strong>Conclusion: </strong>Diagnostic and therapeutic guidelines are necessary due the comparatively high number of cases and the aggressive disease course. Given the low prevalence and the severe impairment of patients, it is often impossible to generate evidence-based data so that ALS guidelines are partially dependent on expert opinion.</p>\",\"PeriodicalId\":19169,\"journal\":{\"name\":\"Neurological Research and Practice\",\"volume\":\"5 1\",\"pages\":\"25\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10268388/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurological Research and Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s42466-023-00251-x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurological Research and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s42466-023-00251-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
2021年,德国神经病学协会(Deutsche Gesellschaft fr Neurology)发布了一份关于运动神经元疾病诊断和治疗的新指南。运动神经元疾病影响初级运动皮层的上运动神经元和/或脑干和脊髓的下运动神经元。肌萎缩侧索硬化症(ALS)是中欧地区最常见的运动神经元疾病,是一种快速进展的疾病,平均寿命为2-4年,年发病率为3.1/10万(Rosenbohm et al. in J Neurol 264(4):749-757, 2017)。https://doi.org/10.1007/s00415 - 017 - 8413 - 3)。它被认为是一种罕见的疾病,主要是因为其发病率低,因为病程短。建议:这些指南包括关于鉴别诊断、神经保护疗法和多学科姑息治疗的建议,包括呼吸和营养管理以及提供辅助装置和临终情况。结论:本病病例较多,病程较急,有必要制定诊断和治疗指南。由于ALS的患病率低,患者的功能严重受损,通常不可能生成循证数据,因此ALS指南部分依赖于专家意见。
Guideline "Motor neuron diseases" of the German Society of Neurology (Deutsche Gesellschaft für Neurologie).
Introduction: In 2021, the Deutsche Gesellschaft für Neurology published a new guideline on diagnosis and therapy of motor neuron disorders. Motor neuron disorders affect upper motor neurons in the primary motor cortex and/or lower motor neurons in the brain stem and spinal cord. The most frequent motor neuron disease amyotrophic lateral sclerosis (ALS) is a rapidly progressive disease with an average life expectancy of 2-4 years with a yearly incidence of 3.1/100,000 in Central Europe (Rosenbohm et al. in J Neurol 264(4):749-757, 2017. https://doi.org/10.1007/s00415-017-8413-3 ). It is considered a rare disease mainly due to its low prevalence as a consequence of short disease duration.
Recommendations: These guidelines comprise recommendations regarding differential diagnosis, neuroprotective therapies and multidisciplinary palliative care including management of respiration and nutrition as well as provision of assistive devices and end-of-life situations.
Conclusion: Diagnostic and therapeutic guidelines are necessary due the comparatively high number of cases and the aggressive disease course. Given the low prevalence and the severe impairment of patients, it is often impossible to generate evidence-based data so that ALS guidelines are partially dependent on expert opinion.